BRBR vs. CERE, PEN, LEGN, BIO.B, PCVX, ASND, VKTX, ITCI, ELAN, and BIO
Should you be buying BellRing Brands stock or one of its competitors? The main competitors of BellRing Brands include Cerevel Therapeutics (CERE), Penumbra (PEN), Legend Biotech (LEGN), Bio-Rad Laboratories (BIO.B), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), Elanco Animal Health (ELAN), and Bio-Rad Laboratories (BIO). These companies are all part of the "medical" sector.
BellRing Brands (NYSE:BRBR) and Cerevel Therapeutics (NASDAQ:CERE) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, community ranking, analyst recommendations, profitability, dividends, valuation and earnings.
BellRing Brands currently has a consensus price target of $62.23, indicating a potential upside of 7.74%. Cerevel Therapeutics has a consensus price target of $42.67, indicating a potential upside of 4.07%. Given BellRing Brands' stronger consensus rating and higher probable upside, equities analysts clearly believe BellRing Brands is more favorable than Cerevel Therapeutics.
Cerevel Therapeutics received 39 more outperform votes than BellRing Brands when rated by MarketBeat users. However, 67.44% of users gave BellRing Brands an outperform vote while only 66.52% of users gave Cerevel Therapeutics an outperform vote.
BellRing Brands has a net margin of 10.39% compared to Cerevel Therapeutics' net margin of 0.00%. BellRing Brands' return on equity of -70.95% beat Cerevel Therapeutics' return on equity.
BellRing Brands has higher revenue and earnings than Cerevel Therapeutics.
95.0% of BellRing Brands shares are held by institutional investors. Comparatively, 87.7% of Cerevel Therapeutics shares are held by institutional investors. 0.8% of BellRing Brands shares are held by company insiders. Comparatively, 5.1% of Cerevel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, BellRing Brands had 2 more articles in the media than Cerevel Therapeutics. MarketBeat recorded 7 mentions for BellRing Brands and 5 mentions for Cerevel Therapeutics. Cerevel Therapeutics' average media sentiment score of 1.19 beat BellRing Brands' score of 0.95 indicating that Cerevel Therapeutics is being referred to more favorably in the news media.
BellRing Brands has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Cerevel Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.
Summary
BellRing Brands beats Cerevel Therapeutics on 11 of the 15 factors compared between the two stocks.
Get BellRing Brands News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRBR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BRBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BellRing Brands Competitors List
Related Companies and Tools
